Tirc7 based diagnostic and therapy of solid cancer

An ex vivo method for diagnosing a cancer patient to have a solid cancer disease which will respond to a TIRC7 modulatory treatment, the method comprising the ex vivo method steps of

• (a) Providing a sample comprising a tumor tissue from said tumor in the cancer patient,
• (b) Determining the expression of TIRC7 in a tumor cell in the tumor tissue or in an immune cell, such as a TIL, in the tumor tissue,
• (c) Depending on the resultant of step (b), diagnosing the patient to have a solid cancer disease which will respond to a TIRC7 modulatory treatment in the event the tumor cell in the tumor tissue and/or the immune cell in the tumor tissue expresses TIRC7 compared to a control cell.

The method according to any of claims 1 to 8, wherein said control cell is a cell not expressing TIRC7 protein (negative control).

A modulator of T cell immune response cDNA 7 (TIRC7) for use in the treatment of lymphoma solid cancer in a patient.

A method for treating a patient suffering from solid cancer, the method comprising the steps of

• (a) Determining the expression of TIRC7 in or on a tumor cell and/or immune cell comprised in a tumor tissue sample from the patient compared to a negative control,
• (b) If the resultant of step (a) is that TIRC7 is expressed in or on the tumor cell and/or immune cell, administering to the patient a therapeutically effective dose of a TIRC7 modulator.